Breast cancer: Modern approaches of diagnostics and treatments

Рак молочной железы: Современные подходы диагностики и лечения
Gulziya Ismailova 1, Bakytgul Yermekbayeva 2, Bakhit Zhussupova 3, Aliya Iskakova 3, Zharilkasin Esmagambetov 4, Galiya Shaimardanova 1, Raushan Kumisbekova 3
More Detail
1 National Scientific Medical Research Center, Astana, Kazakhstan
2 Kazakhstan Nazarbayev University, PI “Centre for Life Sciences”, Astana, Kazakhstan
3 National Scientific Center Oncology and Transplantology, Astana, Kazakhstan
4 Oncology clinic, Astana, Kazakhstan
J CLIN MED KAZ, Volume 4, Issue 34, pp. 10-19.
OPEN ACCESS 3673 Views 2429 Downloads
Download Full Text (PDF)

ABSTRACT

Breast Cancer one of the most widespread cancer form in the world, and from the scientific point of view one of the most studied cancer types. The success of breast cancer treatment depends on staging of the disease, family history, and also HER2 characteristics. The analysis of qualitative characteristics of breast cancer diagnostics, staging and treatment will allow reduce recurrence risk of breast cancer using required standard treatment.
Keywords: breast cancer, chemotherapy, breast conservation surgery, radiotheraphy, cancer hyperthermia, high-quality indicators, HER2 status

CITATION

Ismailova G, Yermekbayeva B, Zhussupova B, Iskakova A, Esmagambetov Z, Shaimardanova G, et al. Breast cancer: Modern approaches of diagnostics and treatments. Journal of Clinical Medicine of Kazakhstan. 2014;4(34):10-9.

REFERENCES

  • Nurgaziev K.Sh., Sejtkazina G.D., Bajpeisov D.M. et al. Pokazateli onkologicheskoj sluzhby Respubliki Kazahstan za 2013 god (statisticheskie materialy) (Indicators Oncology Service of the Republic of Kazakhstan for 2013 (statistical material)), Almaty, 2014, 108 p.
  • Nurgaziev K.Sh., Sejtkazina G.D., Bajpeisov D.M., Sejsenbaeva G.T., Azhmagambetova A.E. Pokazateli onkologicheskoj sluzhby Respubliki Kazahstan za 2011 god (statisticheskie materialy) (Indicators Oncology Service of the Republic of Kazakhstan for 2013 (statistical material)), Almaty, 2012, 108 p.
  • Ismailova G., Rahimzhanova R. Screening for early lung cancer detection with the low-dose computer tomography. J Clin Med Kaz, 2014;2(32): 21-25.
  • Gotzsche PC, Jorgensen KJ. Screening for breast cancer with mammography. Cochrane Database Syst Rev. 2013 Jun 4;6: CD001877. doi: 10.1002/14651858.CD001877.pub5.
  • Tit Albreht, Josep Borras, Fiona Conroy, Miriam Dalmas еt al. European Guide for Quality National Cancer Control Programmes, 2014, 89 p, http://www.epaac.eu/images/WP.
  • Bajgenzhin A.K., Shajmardanova G.M., Popova N.V., Zhusipova B.T., Ismailova G.N. Cirkulirujushhie rakovye kletki: molekuljarnaja harakteristika i monitoring lechenija raka (Circulating tumor cells: molecular characterization and monitoring of cancer treatment), JClinMedKaz, 2013, No.4(30), pp. 9-13.
  • Senkus E., Kyriakides S., Penault-Llorca F., Poortmans P. et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2013, No. 24 (Supplement 6): doi:10.1093/annonc/mdt 284; Published online 22 August 2013.
  • Warner E., Messersmith H., Causer P., Eisen A., Shumak R., Plewes D. Magnetic Resonance Imaging Screening of Women at High Risk for Breast Cancer Toronto (ON): A Quality Initiative of the Program in Evidence - Based Care (PEBC).Cancer Care Ontario (CCO), 2013, Evidence – based Series 15 – 11 Version 2.
  • Rosselli Del Turco M., Ponti A., Bick U., Biganzoli L. et al. Quality indicators in breast cancer care. European Journal of Cance, 2010, pp. 2344–2356.
  • NM Perry and a working group EUSOMA. Multi-disciplinary aspects of quality assurance in the diagnosis of breast disease EUSOMA. European Journal of Cancer, 2001, No.37, pp. 159-172.
  • Blamey R.W., Nicholson R., Miller W., Lonning P.E. et al. Guidelines on endocrine therapy of breast cancer EUSOMA. European Journal of Cancer, 2002, No.38, pp.615–634.
  • Kurtz J. and a working group EUSOMA. The curative role of radiotherapy in the treatment of operable breast cancer, European Journal of Cancer, 2002, No.38, pp.1961–1974.
  • Galimberti V, Cole BF, Zurrida S, Viale G. et al. International Breast Cancer Study Group Trial 23-01 investigators. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol, 2013, No.14, pp.297–305.
  • Bryan P. Schneider, Robert J. Gray, Milan Radovich, Fei Shen. et al. Prognostic and predictive value of tumor VEGF gene with and without bevacizumab; results from ECOG 2100 trial amplification in metastatic breast cancer treated with paclitaxel, Clin Cancer Res, 2013, Published Online First January 22, DOI: 10.1158/1078-0432.CCR-12-3029.
  • Gunter von Minckwitz, Holger Eidtmann, Mahdi Rezai, Peter A. Fasching. et al. Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer N Engl J Med, 2012, No.366, pp.299-309.
  • José Baselga, Javier Cortés, Sung-Bae Kim, Seock-Ah Im.ey al. Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer, NEngl J Med, 2012, No.366, pp.109-119.
  • Lisa Ryde´n, Karin Jirstro¨m, Monica Haglund, Olle Stal et al. Epidermal growth factor receptor and vascular endothelialgrowth factor receptor 2 are specific biomarkers in triple-negativebreast cancer. Results from a controlled randomized trial with long-term follow-up, Breast Cancer Res Treat, 2010, No.120, pp.491–498
  • W. J. Gradishar, Emerging approaches for treating HER2-positive metastatic breast cancer beyond trastuzumab, Annals of Oncology, 2013, No. 24, pp.2492–2500
  • Guarneri V, Frassoldati A, Piacentini F et al. Preoperative chemotherapy plus lapatinib or trastuzumab or both in HER2-positive operable breast cancer (CHERLOB Trial), Clin Breast Cancer, 2008, No.8, pp.192–194.
  • Swain S. M., Baselga J., Miles D. et al. Incidence of central nervous system metastases in patients with HER2-positivemetastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA, Annals of Oncology, 2014, Advance Access published March 31,
  • Cardoso F., Harbeck N., Fallowfield L. et al. Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Annals of Oncology, 2012, No.23 (Supplement 7), vii11–vii19, doi:10.1093/annonc/mds 232
  • CDF SELCN documentation, April 2012 http://www.medicines.org.uk
  • Miles D, Bridgewater J, Ellis P, Harrison M. et al. Using bevacizumab to treat metastatic cancer: UK consensus guidelines, Br J Hosp Med (Lond), 2010, No.71(12), pp.670-677.
  • Malyshev N, Dossakhanov A, Kostrova E, Bochkova N. et al. Radiomodification by capecitabine and arglabin in radiation therapy of breast cancer patients, Annals of Oncology, 2006, No. 7(Supplement 9): ix69–ix92, doi:10.1093/annonc/mdl205
  • Dossakhanov A.H., Kostrova E.V., Bochkova N.V., Sirota V.B. Radiomodifikacija arglabinom i kselodoj pri nestandartnom frakcionirovanii pri rake molochnoj zhelezy (Radiomodification Arglabin and Xeloda with non-standard fractionation for breast cancer), Rossijskij bioterapevticheskij zhurnal, 2006, No.1(5), pp.43.
  • Galea MH, Blamey RW, Elston CE, Ellis IO. The Nottingham Prognostic Index in primary breast cancer, Breast Cancer Research & Treatment, 1992, No.22(3), pp.207-219. 
  • Ismailova G., Aydarhanova K., Demessinov A., Aubakirova A. Health economic rates for medical services and clinical economic analysis as components of health reform in Kazakhstan, Medical and Health Science Journal/MHSJ/, 2010, 1-7
  • National Medical Policy. Circulating Tumor Cells. Policy Number: NMP 513. Effective Date: June 2014.
  • Association of Breast Surgery at Baso 2009. Guidelines. Surgical guidelines for the management of breast cancer, Eur J SurgOncol, 2009, No.35(Suppl 1), pp. 1–22.
  • E. Shelley Hwang, Daphne Y. Lichtensztajn, Scarlett Lin Gomez, Barbara Fowble, Christina A. Clarke. Survival after lumpectomy and mastectomy for early stage invasive breast cancer: the effect of age and hormone receptor status,Cancer,2013, No.119, pp.1402– 1411
  • Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomized trials, Lancet, 2011, No.378, 1707–1716.
  • Skowronek J, Wawrzyniak-Hojczyk M, Ambrochowicz K. Brachytherapy in accelerated partial breast irradiation (APBI) – review of treatment methods, J Contemp Brachytherapy, 2012, No.4(3), pp.152–164.
  • National Medical Policy. Hyperthermia for Treatment of Breast Cancer. Policy Number: NMP424. Effective Date: July 2014.
  • Miles DW, Diéras V, Cortés J, Duenne AA, Yi J, O’Shaughnessy J. First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients, Ann Oncol, 2013 No.24(11), pp.2773-2780.
  • Qi WX, Shen Z, Tang LN, Yao Y. Bevacizumab increases the risk of gastrointestinal perforation in cancer patients: a meta-analysis with a focus on different subgroups, Eur J ClinPharmacol, 2014, No.70(8), pp.893-906.
  • Huang H, Zheng Y, Zhu J, Zhang J, Chen H, Chen X. An Updated Meta-Analysis of Fatal Adverse Events Caused by Bevacizumab Therapy in Cancer Patients PLoS ON, 2014, No. 9, Issue 3, e89960: Published March 5.
  • National Medical Policy.Adoptive Immunotherapy for Cancer. Policy Number: NMP265. Effective Date: May 2014.
  • Geller MA, Cooley S, Judson PL, Ghebre R, Carson LF, Argenta PA. et al. A phase II study of allogeneic natural killercell therapy to treat patients with recurrent ovarian and breast cancer, Cytotherapy, 2011, No.13(1), pp.98-107.
  • Ali H. R., Provenzano E., Dawson S.J., Blows F. M. et al. Caldas Association Between CD8+ T-cell Infiltration and Breast Cancer Survival in 12 439 Patients, Ann Oncol, 2014, No.25(8), pp.1536-1543.
  • Richardz Dzhon M. (US), Moriarti Jenn (US), Peterson Per A. (US), Caj Czelin (US) Patent na izobretenie (RU 2447900). Lechenie raka, kombinirujushhee limfoistoshhajushhee veshhestvo s ctl i citokinami (A patent for an invention (RU 2447900). Cancer Treatment combining limfoistoschayuschee substance with CTL and cytokines).